Literature DB >> 34914890

Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study.

Maria Reig1, Marco Sanduzzi-Zamparelli2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34914890     DOI: 10.1016/S1470-2045(21)00651-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  N4BP3 promotes angiogenesis in hepatocellular carcinoma by binding with KAT2B.

Authors:  Hexu Han; Wei Zhu; Ting Lin; Cuixia Liu; Hengyong Zhai
Journal:  Cancer Sci       Date:  2022-08-01       Impact factor: 6.518

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.